Eli Lilly's Zepbound is the first and only approved dual GLP-1/GIP agonist, and Lilly is also working on its own triple ...

Novo Nordisk has rebounded strongly in 2025, backed by solid financials despite earlier setbacks and competitive risks. See ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Novo Nordisk A/S shares are staging a comeback after a tumultuous year for the maker of Ozempic and Wegovy. The stock is up ...

On top of that, an analyst cut his price target on the Denmark-based pharmaceutical company. Novo Nordisk (NYSE: NVO) stock ...

NVO jumps nearly 6% in a week on amycretin pipeline boost and hedge fund interest, but competition looms large.

The analyst is thus maintaining a cautious stance on the stock. Novo Nordisk A/S (NYSE:NVO) is a global healthcare company ...

TD Cowen reiterated its Buy rating and $105.00 price target on Novo Nordisk (NYSE: NVO) Wednesday following meetings with the company’s senior leadership in Copenhagen. The pharmaceutical giant, with ...

It has been reported that Novo Nordisk may have inadvertently allowed generics of its GLP-1 agonist semaglutide, the active ...

Facing relentless bullying and health issues linked to obesity, some American teens are turning to Wegovy, a weight-loss drug ...

Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website ...